Medicamen Biotech (531146) Stock Overview
A pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
531146 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Medicamen Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹308.75 |
| 52 Week High | ₹630.00 |
| 52 Week Low | ₹292.50 |
| Beta | 0.55 |
| 1 Month Change | -12.15% |
| 3 Month Change | -23.34% |
| 1 Year Change | -45.56% |
| 3 Year Change | -68.56% |
| 5 Year Change | -22.61% |
| Change since IPO | 2,097.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531146 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.5% | 1.4% | 1.5% |
| 1Y | -45.6% | -7.2% | -4.7% |
Return vs Industry: 531146 underperformed the Indian Pharmaceuticals industry which returned -7.2% over the past year.
Return vs Market: 531146 underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| 531146 volatility | |
|---|---|
| 531146 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 531146 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531146's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 376 | Rajesh Madan | www.medicamen.com |
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management.
Medicamen Biotech Limited Fundamentals Summary
| 531146 fundamental statistics | |
|---|---|
| Market cap | ₹3.93b |
| Earnings (TTM) | ₹79.10m |
| Revenue (TTM) | ₹1.63b |
Is 531146 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531146 income statement (TTM) | |
|---|---|
| Revenue | ₹1.63b |
| Cost of Revenue | ₹832.39m |
| Gross Profit | ₹793.04m |
| Other Expenses | ₹713.94m |
| Earnings | ₹79.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.22 |
| Gross Margin | 48.79% |
| Net Profit Margin | 4.87% |
| Debt/Equity Ratio | 15.6% |
How did 531146 perform over the long term?
See historical performance and comparisonDividends
Does 531146 pay a reliable dividends?
See 531146 dividend history and benchmarks| Medicamen Biotech dividend dates | |
|---|---|
| Ex Dividend Date | Sep 19 2025 |
| Dividend Pay Date | Oct 26 2025 |
| Days until Ex dividend | 15 days |
| Days until Dividend pay date | 22 days |
Does 531146 pay a reliable dividends?
See 531146 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 04:54 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicamen Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |